Diligence memo · auto-generated · as of July 2, 2026

EternoGen Aesthetics, LLC

EternoGen Aesthetics, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

EternoGen Aesthetics, LLC operates in Biotechnology, based in COLUMBIA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

EternoGen Aesthetics, LLC has raised $939K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $839K on 2014-10-14.

Most recent recorded round closed around 2014-10-14.

Valuation (modeled)modeled

Provath models EternoGen Aesthetics, LLC at approximately $46M (range $447K–$525M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.92× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 11.7 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 8.4× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 17% of Biotechnology peers (4293 compared).

Modeled value ranks above 44% of those peers.

Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.